Leiden, The Netherlands, December 1, 2008. Biotech company PharmingGroup NV ("Pharming" or "The Company") (Euronext: PHARM) announcedtoday that Prof. Dr. B.P.Th. Veltman has notified the Company that hewill retire from the Board of Supervisory Directors ("BOSD")effective December 1, 2008. Reaching the age of 76, Dr. Veltman hadalready previously announced that he had plans to retire from theBOSD at the Annual General Meeting in 2009. Personal circumstanceshave led him to take this decision at this moment.

Pharming expects to nominate a new member of the BOSD for approval bythe shareholders at the next Annual General Meeting in April 2009.

Mr Jaap Blaak, Chairman of Pharming's Board of Supervisory Directorssaid: "Pharming is very grateful to Dr. Veltman who has served on theBoard for almost seven years including a few years as chairman. Hisextensive knowledge and experience in the Academic world as well asin several high-tech companies has been very important for Pharming'sdevelopment over the last seven years. Dr. Veltman made many valuablecontributions during this period. We regret, but understand andaccept, his wish to retire at this moment."

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatmentof genetic disorders, ageing diseases, specialty products forsurgical indications, intermediates for various applications andnutritional products. Pharming has two products in late stagedevelopment - Rhucin® for Hereditary Angioedema and human lactoferrinfor use in food products. The advanced technologies of the Companyinclude innovative platforms for the production of proteintherapeutics, technology and processes for the purification andformulation of these products, as well as technology in the field ofDNA repair (via DNage). Additional information is available on thePharming website, http://www.pharming.com.

This press release contains forward looking statements that involveknown and unknown risks, uncertainties and other factors, which maycause the actual results, performance or achievements of the Companyto be materially different from the results, performance orachievements expressed or implied by these forward lookingstatements.

Contact:

Carina Hamaker, Investor Voice, T: +31 (0)6 537 499 59 or T: +31(0)71 52 47 400Julia Phillips (UK), Financial Dynamics, T: +44 (0)20 7269 7187 or T:+44 (0)7770 827 263Samir Singh (US), Pharming Group NV, T: +1 908 720 6224Rein Strijker, Pharming Group NV, T: +31 (0)71 52 47 400

This announcement was originally distributed by Hugin. The issuer issolely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.